Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27921424 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL8648898 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL19475556 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL7094225 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL2413753 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL25166887 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL1898656 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| SCHEMBL181028 | 1.00 | LMNA (0.43) | LMNAKDM4EALOX15LGALS8CD69 | |
| Hydrochloric Acid SCHEMBL28256651 | 0.98 | LMNA (0.42) | LMNAKDM4EALOX15LGALS8CD69 | |
| Ammonia Solution, Strong SCHEMBL27636528 | 0.98 | LMNA (0.42) | LMNAKDM4EALOX15LGALS8CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3024848-A1 | METHODS AND COMPOSITIONS FOR INCREASING ENZYME ACTIVITY IN THE CNS | ArmaGen Technologies, Inc. (US) | 2016-06-01 | — | — | EP | claimed |
| WO-2015012944-A1 | METHODS AND COMPOSITIONS FOR INCREASING ENZYME ACTIVITY IN THE CNS | ARMAGEN TECHNOLOGIES, INC (US) | 2015-01-29 | — | — | WO | claimed |
| EP-4337774-A1 | PROGRAMMABLE NANOENCAPSULATION FOR DELIVERY OF PROBIOTICS IN VIVO | The Trustees of Columbia University in the City of New York (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4225338-A1 | ENGINEERED PROBIOTICS FOR EXPRESSION OF FIBER-SYNTHESIZING ENZYMES IN GUT | Zbiotics Company (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023110854-A1 | METHODS OF PRODUCTION OF HEPAROSAN, HEPARAN SULFATE AND HEPARIN IN YEAST | GENHTIS FINE CHEMICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022241107-A1 | PROGRAMMABLE NANOENCAPSULATION FOR DELIVERY OF PROBIOTICS IN VIVO | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-11-17 | — | — | WO | disclosed |
| EP-3119894-A1 | COTTON FIBERS WITH INCREASED GLUCOSAMINE CONTENT | Bayer CropScience NV (BE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3024848-A1 | METHODS AND COMPOSITIONS FOR INCREASING ENZYME ACTIVITY IN THE CNS | ArmaGen Technologies, Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015140191-A1 | COTTON FIBERS WITH INCREASED GLUCOSAMINE CONTENT | BAYER CROPSCIENCE NV (BE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015012944-A1 | METHODS AND COMPOSITIONS FOR INCREASING ENZYME ACTIVITY IN THE CNS | ARMAGEN TECHNOLOGIES, INC (US) | 2015-01-29 | — | — | WO | disclosed |
| EP-2596123-A2 | CRYSTAL STRUCTURE OF HUMAN ALPHA-N-ACETYLGLUCOSAMINIDASE | Shire Human Genetic Therapies, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2585105-A2 | TREATMENT OF SANFILIPPO SYNDROME TYPE B | Shire Human Genetic Therapies, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012012742-A2 | CRYSTAL STRUCTURE OF HUMAN ALPHA-N-ACETYLGLUCOSAMINIDASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011163652-A2 | TREATMENT OF SANFILIPPO SYNDROME TYPE B | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| EP-1185283-A4 | NOVEL THERAPEUTIC USE OF VIRAL INFLAMMATION MODULATORY PROTEIN IN BLOCKING XENOGRAFT REJECTION | KING FAISAL SPECIALIST HOSPITA (SA) | 2003-07-02 | — | — | EP | disclosed |
| EP-1185283-A1 | NOVEL THERAPEUTIC USE OF VIRAL INFLAMMATION MODULATORY PROTEIN IN BLOCKING XENOGRAFT REJECTION | KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTRE (SA) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000071147-A1 | NOVEL THERAPEUTIC USE OF VIRAL INFLAMMATION MODULATORY PROTEIN IN BLOCKING XENOGRAFT REJECTION | KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTRE (SA) | 2000-11-30 | — | — | WO | disclosed |